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  Oral cancer constitutes the sixth most common cancer 
worldwide and accounts for approximately 5% of all  malignant 
tumours worldwide.1 In India and South East Asia, Oral Squamous 
Cell Carcinoma (OSCC) is the third most common malignancy 
constituting 50% of all  malignant tumours.1  OSCC is the most 
common type of oral cancer and is often preceded by or associated 
with potentially malignant lesions or conditions such as leukoplakia 
and oral submucous fibrosis.2   
 Oral leukoplakia (OL) is “a white patch or plaque that cannot 
be characterized clinically or pathologically as any other disease”.¹  
It is  the most common potentially malignant lesion of the oral 
mucosa. Tobacco and areca nut chewing (alone or in combination 
such as paan) are the habits that are positively associated with oral 
leukoplakia.3  
 Chewing areca nut containing betel quid without tobacco is an 
independent risk factor for developing oral cancer. When betel quid 
with tobacco is consumed with alcohol and smoking the relative risk 
increases eleven fold. 4  
 The malignant transformation rate for leukoplakia ranges 
from 5-20% and is particularly correlated with the degree of 
dysplasia.3  The grading of epithelial dysplasia remains subjective as 
it  relies on cellular atypia and architectural disturbances.  It  is 
important to identify markers that could help us to ascertain the 
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malignant transformation of potentially malignant lesions to target 
them for aggressive treatment.  5  
 NF-κ  B is a family of nuclear transcription factors identified 
by Sen and Baltimore in 1986. It   is  involved  in  immune  response  
and comprises of  hetero or  homo dimers of 5 different subunits  
NF-κB1, NF-κB2, REL A, REL B, cREL. NF-κB’s are transiently 
activated in response to infection or injury and are aberrantly 
activated in cancers contributing to their pathogenesis and 
therapeutic resistance.6  
 NF-κB is bound to inhibitor -kappa B (IκB) and is found in 
the cytoplasm of cells in an inactive form known as the canonical or 
classical form of NF-κB.  In response to stimulus by  growth factors 
or cytokines, IκB is phosphorylated, ubiquitinated  and degraded by  
proteosome  resulting  in the activation of  NF-κB which 
translocates  to the nucleus and regulates target genes involved  in 
immunoregulation, inflammation, proliferation and  apoptosis.7  
 NF-κB is involved in the regulation of cell-cycle and 
apoptosis, thus playing an important role in cell  proliferation and 
survival.  Inappropriate NF-κB activation can mediate oncogenesis 
and tumor progression.8 It  is  known to inhibit apoptosis through the 
induction of anti-apoptotic proteins, and to suppress the apoptotic 





 The present study was done to evaluate and compare the 
expression of NF-κB in formalin fixed paraffin embedded tissues of 


























Aim of the study 
 To assess NF-κB expression in Oral squamous cell carcinoma, 
leukoplakia and normal buccal mucosa. 
Hypothesis (null) 
 There is no difference in the expression of NF-κB in oral 
squamous cell carcinoma and leukoplakia when compared with 
normal buccal mucosa. 
Objectives of the study 
A. To evaluate the expression of NF-κB in formalin fixed 
paraffin embedded tissues of normal buccal mucosa by 
immunohistochemistry.  
B.  To evaluate the expression of NF-κB in formalin fixed 
paraffin embedded tissue of oral squamous cell carcinoma 
from patients by immunohistochemistry.  
•  With areca chewing habit  
•  With tobacco chewing habit 
•  With both areca and tobacco chewing 
•  With both smoking and chewing 
C. To evaluate the expression of NF-κB in formalin fixed 
paraffin embedded tissue of oral leukoplakia (epithelial 
dysplasia) by immunohistochemistry. 
D. To compare the expression of NF-κB n oral squamous cell 





Study Design  
 A retrospective study was conducted in Department of Oral 
and Maxillofacial Pathology, Ragas Dental College & Hospital,  
Chennai, using archival paraffin embedded tissues. 
Study samples  
 The study material comprised of 80 formalin fixed, paraffin 
embedded tissue specimens (archival blocks). 
•  Forty (n=40) histopathologically confirmed OSCC tissue 
specimens. 
•  Twenty (n=20) histopathologically confirmed epithelial 
dysplasia tissue specimens 
•  Twenty (n=20) normal buccal mucosa tissue specimens  
Study subjects 
The study comprised of 3 groups: 
Group 1  – (CASES)          
Forty tissue blocks from patients diagnosed with OSCC clinically 
and confirmed histopathologically.  
Group 2- (CASES)  
Twenty tissue blocks from patients diagnosed with leukoplakia 
clinically and confirmed histopathologically as epithelial dysplasia. 
Group 3- (CONTROLS) 
 Twenty patients who had clinically normal buccal mucosa, 
reporting to the outpatient department of oral and maxillofacial 
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surgery for removal of impacted third molar constituted the control 
group. 
Inclusion Criteria 
• They had no habit of smoking, alcohol consumption or 
chewing areca nut. 
• They were apparently healthy with no systemic disorders. 
• They were not on any medications for systemic diseases like 
hypertension, diabetes. 
Methodology 
1. A detailed case history including age, sex and occupation, past 
medical and dental history, history of habits,  drugs and trauma 
were recorded. 
2. General examination and intraoral examination was done. 
3. Biopsy was done in both cases and controls. 
4. The tissue taken was immediately transferred to 10% buffered 
formalin  
5. After adequate fixation, tissues were embedded in paraffim. 
6. From the paraffim embedded blocks 4 micron thick, sections 
were cut and used, for routine hematoxylin and eosin (H&E) 
staining and Immunohistochemical (IHC) staining. 
7. This project was approved  by Institutional Review Board  (IRB)  
of Ragas Dental College & Hospital,  Chennai  
8. Patient consent was taken for those patients from whom normal 




HEMATOXYLIN & EOSIN STAINING 
Reagents 
• Harry’s hematoxylin 
• 1% acid alcohol 
• Eosin 
Procedure 
• The slides were deparaffinised in xylene and hydrated 
through graded alcohol to water. 
• The sections on the slides were flooded with Harry’s 
hematoxylin for 5 minutes. 
• The slides were washed in running tap water for 5 minutes. 
• The slides were differentiated in 1% acid alcohol for 5 
minutes.  
• The slides were washed well in running tap water for 5 
minutes.  
• The tissue sections on the slides were then stained in eosin 
for 30 seconds. 
• The slides were washed in running tap water for 1 minute. 
• The slides were then dehydrated through alcohol, cleared, 
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1. Conc. HCl 
2. Laxbro soln 
3. APES (3 amino propyl tri ethoxy silane) 
4. Acetone 
5. Citrate buffer 
6. Phosphate Buffer Saline (PBS) 
7. 3% H2O2 
8. Deionized distilled water 
9. Haematoxylin 
10. Absolute alcohol 
11. Xylene 
Antibodies used  
1.  Primary antibody – NF-κB (p50) Rabbit polyclonal antibody 
(SantaCruz). 
2.  Secondary antibody – SC-2018 Rabbit Avidin Biotin Complex 
staining system (SantaCruz). 
IHC Procedure 
Pretreatment of the slides 
• The slides were first washed in tap water for few minutes 
• The slides were then soaked in detergent solution for 1 hour 
• After 1 hour,  each slide was brushed individually using the 
detergent solution and were transferred to distilled water. 
• The slides were washed in two changes of distilled water. 
• The slides were washed in autoclaved distilled water. 
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• The slides were immersed in 1 N HCL (100 ml HCl in 900 ml 
distilled water) overnight. 
• The following day slides were taken out of acid and washed in 
two changes of autoclaved distilled water. 
• All the slides were then transferred to slide trays, wrapped in 
aluminium foil and baked in hot air oven for 4 hours at 180 
degrees centigrade. 
APES (3 Amino propyl tri ethoxy silane) coating 
Slides first dipped in couplin jar containing acetone for 2 minutes  
 
Dipped in APES for 5 minutes 
 
Dipped in two changes of distilled water for 2 minutes each and 
slides were left to dry 
Preparation of paraffin sections 
 After the slides were dry, tissue section of 4µ thickness were 
made in a rotary manual microtome. The ribbons of tissue section 
were transferred onto the APES coated slide from the tissue float 
bath such that two tissue bits come on to the slide with a gap in 
between. One of the tissue sections was labeled positive (P) and the 








 The slides with tissue sections were treated with three 
changes of xylene to remove paraffin wax. They were put in 
descending grades of alcohol and then rehydrated with water. Slides   
were then treated with 3% hydrogen peroxide for 30 minutes to 
quench endogenous peroxidase activity of cells that would 
otherwise result in non – specific staining. Then the slides were 
transferred to citrate buffer and autoclaved for antigen retrieval at  
15 lbs pressure for 30 minutes. Then the slides were dipped in 3 
changes of distilled water for 5 minutes each. Circles were drawn 
around the tissues, so that the antibodies added later on do not 
spread and are restricted to the circle. The tissues were incubated in 
protein blocking serum for one hour in an enclosed hydrated 
container. Then the slides were wiped carefully without touching 
the tissue section to remove excess of blocking serum. The primary 
antibody, rabbit polyclonal antibody, 1:50 dilution was added to 
positive tissue on the slide and then to the N, PBS was added. The 
slides were incubated for one hour. Then the slides were wiped 
carefully without touching the tissue section to remove excess of 
antibody and washed with three changes of cold PBS for 5 minutes.  
Then a drop of biotin conjugated secondary antibody was added on 
both the sections and the slides were incubated for 30 minutes. 
Later slides were washed in three changes of cold PBS for 5 minutes 
in each. The slides were wiped carefully without touching the tissue 
section to remove excess PBS. Then a drop of avidin biotin enzyme 
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reagent was added on both the sections and the slides were 
incubated for 30 minutes. The sections were washed in 3 changes of 
cold PBS for 5 minutes in each. Then the slides were wiped 
carefully without touching the tissue section to remove excess PBS. 
Then a drop of freshly prepared DAB (3’–Diaminobenzidine Tetra 
Hydrochloride – a substrate chromogen) was added on both sections. 
Slides were then washed in distilled water to remove excess DAB 
and counter stained with hematoxylin. The slides were placed in a 
tray with tap water for bluing. Then the slides were transferred to 
70% alcohol, 100% alcohol and one change of xylene. The tissue 
sections were mounted with Di-n-butyl phthalate. The slides were 
then observed under the microscope. Throughout the procedure care 
was taken not to dry the tissues. 
Positive Control  
A known case of  NF-κ  B positive oral squamous cell carcinoma 
specimen tissue were fixed, processed, embedded, sectioned and 
stained  in same  manner and used  as  positive control.  One positive 
control tissue slide was included for each batch of IHC procedure. 
IHC PROCEDURE FLOW CHART 
APES coated slides with 2 paraffin embedded tissues 
 
Placed in xylene thrice (5 minutes each) 
 




Placed in 70% isopropanol (5 minutes) 
 
Washed in distilled water thrice (5 minutes each) 
 
Placed in 3% hydrogen peroxide (20 minutes) 
 
Kept in citrate buffer at pH 6 and autoclaved for antigen retrieval 
and bench cooled  for 40 minutes 
 
Washed in distilled water thrice (5 minutes each) 
 
Protein blocking serum added and incubated for one hour 
 
Primary antibody added to the specimen and incubated for one hour 
 
Washed in PBS thrice (5 minutes each) 
 
Secondary antibody added and incubated in an enclosed hydrated 
container (30 minutes) 
 
Washed in PBS thrice (5 minutes each) 
 
avidin biotin enzyme reagent added and incubated (30 minutes) 
 




DAB added and incubated in an enclosed hydrated container  
(5 minutes) 
 
Washed in PBS thrice (5 minutes each) 
 
Stained with haematoxylin (20 seconds) 
 
Washed in tap water 
 
Placed in 70% isopropanol (1 minute) 
 
Placed in 90% isopropanol (1 minute) 
 
Placed in 100% isopropanol (1 minute) 
 
Placed in xylene (1 dip) 
 
Slides were mounted using DPX 
 







Criteria for evaluation of NF-κ  B staining 
The following parameters were used to evaluate NF-κ  B  staining 
1. Tissue localization of stain  – Location of NF-κ  B staining 
either in the epithelium and /or connective tissue was 
recorded. In the epithelium staining in the basal and /or 
suprabasal layers was recorded.  
2. Cellular localization of stain – Nucleus and /or cytoplasm 
3. Intensity of the stain  – In each of the positive case the entire 
tissue was graded as no stain (0),  mild (+), moderate (++), 
and intense (+++). 
4. Labelling index (LI) – was calculated by dividing the number 
of positive cells by the total  number of cells counted  in the 
slide and expressed as percentage. A minimum of thousand 
cells was counted for each slide.  
 
 
     Number of positive cells 
LI =  Ӎ  Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ   Ӎ  X 100 









 Statistical  analysis was done using SPSS T M  software (version 
10.0.5). p value ≤0.05 was considered to be statistically significant. 
 
• Pearson’s Chi-square test was done to compare mean age, the 
distribution of gender and habits,  t issue localization of stain, 
cellular location, nature of stain, intensity of stain and the 
percentage of cells stained among the three study groups. 
• The inter-observer variability for the intensity of stain was 
assessed by 2 investigators and their reports were confirmed with 
kappa statistics. 
• The mean labeling index between the groups was analysed by 
















STRUCTURE AND MOLECULAR MECHANISM OF NF- κ  B 
 NF-κB described in 1986, by Baltimore. D was characterized 
initially from B-lymphocytes as a nuclear factor necessary for the 
transcription of the immunoglobulin κ  l ight chain gene.  
 Nuclear factor-kappaB  (NF-κB) is a collective term that 
refers to a small class of dimeric transcription factors for a number 
of genes, including growth factors, angiogenesis modulators, cell-
adhesion molecules and antiapoptotic factors.9 Although most NF-
κB proteins promote transcription, some act as inactivating or 
repressive complexes. The most common dimer known 
“specifically” as NF-κB, is relatively abundant, controls the 
expression of numerous genes and exist as an inactive cytoplasmic 
complex bound to inhibitory proteins of the NF-κB inhibitory (Iκ  B) 
family.10  
 The inactive NF-κB –IκB complex is activated by a variety of 
stimuli,  including proinflammatory cytokines, mitogens, growth 
factors and stress-inducing agents. The release of NF-κB facilitates 
its translocation to the nucleus, where it  promotes cell survival by 
initiating the transcription of genes encoding stress-response 
enzymes, cell-adhesion molecules, proinflammatory cytokines and 






MEMBERS OF THE FAMILY 
 NF-κB is a family of signal activated transcription factors 
comprised of hetero-or homo-dimers from 5 different subunits,  NF-
κB1, NF-κB2, RELA, c REL and RELB. NF-κBs normally are 
transiently activated in response to infection or injury, but in 
cancers are aberrantly activated, regulating a transcriptome of 
hundreds of genes and corresponding proteosome that promote 
pathogenesis and therapeutic resistance.1 2  
 NF-κB1 is transcribed as  p105 and  processed  to p50,  NF-
κB2  is transcribed as p100 and  processed to p52 following 
phosphorylation and proteosome-dependent degradation of their 
ankyrin repeat –containing c-termini.  RELA, RELB and cREL are 
synthesized in mature form and often form hetero dimers with NF-
κB1 or NF-κB2.1 3  
ACTIVATION OF NF-κB   
There are two pathways that lead to the activation of NF- κB.  
 Canonical /  Classical pathway.  
 Non – canonical / alternate pathway.  
 NF-κB1 is often associated with RELA (or cREL) and bound 
in the cytoplasm in an inactive form by Inhibitor-kappaB (IκB)- α ,  β  
or γ ,  and known as the canonical,  or classical form of NF-κB. This 
form is activated by various components of pathogens or cytokines 
such as Tumor Necrosis Factor (TNF) or Interleukin-1 (IL-1), 
primarily via a trimeric Inhibitor-kappaB Kinase (IKK) comprised 
of α ,  β  and γ  subunits,  that phosphorylates IκB, leading to IκB 
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proteasomal degradation and nuclear translocation and DNA binding 
of the NF-κB1/RELA heterodimer.1 4  
 NF-κB2 often forms a heterodimer with RELB, known as the 
non-canonical form of NF-κB. The non-canonical or alternate 
pathway is activated by other stimuli such as lymphotoxin B, BAFF 
and CD40L, via an NF-κB Inducing Kinase (NIK) and IKKα  dimeric 
complex.15  
 Aberrant activation of canonical pathway has been broadly 
implicated in development of many cancers, consistent with its 
ubiquitous expression and role in promoting cell survival and 
growth. Aberrant activation of the non- canonical pathway has been 
demonstrated in B lymphoid malignancies, as well as other 
cancers.16  
INHIBITION OF NF-κB 
 IκB is a large family of inhibitory molecules that includes 
IκBα ,  IκBβ ,  IκBԖ ,  IκBγ  and Bcl-3. The IκB are characterized by the 
presence of multiple ankyrin repeats and interact with NF- κB via 
RHD. The RHD serves several functions; this domain can act as the 
dimerization and DNA binding domain of this class of proteins as  i t  
contains nuclear localization sequence  and it  is  the site for binding 
of IκB.  NF – κB binds to 9 - 10 base pair DNA sites (κB sites) as 
dimers. The activity of NF - κB is primarily regulated by interaction 
with inhibitory IκB proteins. 17  
 IκB kinase (IKK) is present in the cell cytoplasm as an 
enzyme with serine-protein-kinase activity that is  responsible for 
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IκBα  phosphorylation and that links tumor necrosis factor (TNF) – 
induced and interleukin-1 (IL-1)-induced kinase cascades to NF-κB 
activation. It  is  a large, multisubunit complex with three known 
components.  Two of these polypeptide components, IKKα  and IKKβ  
are catalytic subunits,  whereas the third component, IKKα  (NEMO), 
has a regulatory function. In most cells,  NF-κB is present as a 
latent,  inactive IκB – bound complex in the cytoplasm.1 8 The 
stimulation by different pathogens and other inducers including 
viruses. Cytokines lead to the activation of signaling cascades that 
activates the IκB complex and causes phosphorylation of IκB. The 
NF–κB is then released and translocated to the nucleus where they 
bind with target genes and regulate their transcription. 1 9  
ROLE OF NF-κB IN CELL CYCLE REGULATION 
 The inactive NF-κB-IκB complex is activated by a variety of 
stimuli,  including pro inflammatory cytokines, nitrogens, growth 
factors and stress-inducing agents. Pro-inflammatory cytokines 
produced by macrophages, T cells and other cells exert their actions 
on target cells by transactivating NFκB (i.e.,  by initiating the signal 
cascade).2 0  Most cells express receptors for the pro-inflammatory 
cytokines, IL-1β  and TNF-α ,  and they also contain the IKK complex 
needed for signal transduction. Cells such as leukocytes, vascular 
endothelial and smooth muscle cells,  cardiomyocytes and fibroblasts 
therefore respond to proinflammatory cytokines by NF-κB 
activation.2 1  
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 NF-κB activation induces the expression of pro-inflammatory 
cytokines in a positive feed-back loop. The NF-κB pathway is used 
not only by pro-inflammatory cytokines but also by microbial 
products. In particular,  endotoxins of gram-negative bacteria signal 
through NF-κB. Different stimuli initiates different signal-
transduction pathways,  which are activated by their respective 
ligands.2 2 NF-κB then translocates to the nucleus where, by binding 
to κB, it  initiates transcription of various cytokines, adhesion 
molecules, vascular endothelial growth factor etc. These 
transcription products aid in further proliferation of cells.2 3  
 NF-κB plays a critical role in cell cycle progression during 
G0-to-G1 phase. Inhibition of NF-κB caused impairment of cell 
cycle progression, retarded G1 to S-phase transition. Passage 
through the restriction point in G1 and transit into S phase requires 
the sequential activation of cyclin-dependent kinases (CDK4, 
CDK6, CDK2) in complex with their particular G1 cyclins (D or E). 
The D family of cyclins (D1, D2, D3) in complex with the catalytic 
subunits CDK4 and CDK6 are the primary holoenzymes required for 
entry and passage through G1.  NF-κB promotes cell cycle 
progression by regulating the expression of several genes involved 
in the cell cycle machinery such as cyclin D1, D2, D3, E and c-
myc.2 4  
DUAL ROLE OF NF-κB 
 NF-κB plays a major role as a mediator in inhibition of 
apoptosis in many cell types. Tumor initiation begins with the 
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prolonged survival of a cell and so, NF-κB’s role has an obvious 
implication for cancer. An anti-apoptotic role of NF-κB has been 
linked to T cell lymphoma, osteoclasts,  melanoma, pancreatic 
cancer, bladder cancer and breast cancer. Cell types that display an 
anti-apoptotic role for NF-κB include B cells,  T cells,  granulocytes, 
macrophages, neuronal cells and smooth muscle cells.25  
 NF-κB has been shown to play a pro-apoptotic role in 
addition to its more common anti-apoptotic role. Different 
activation pathways of NF-κB may cause the expression of proteins 
that promote apoptosis (eg: Fas, c-myc, p53, IκBα) or inhibit 
apoptosis (eg: TRAF2, IAP proteins, Bcl-2 like proteins).  NF-κB 
activation variably controls the regulation of cell cycle proteins (eg: 
cyclin D1 and CDK2 kinase) and the interaction with various 
cellular components (eg: p300 and p53) that promote or induce 
apoptosis.2 6  
ROLE OF NF-κB IN CANCER 
 NF-κB has been implicated in carcinogenesis because of its  
critical  roles in cell  survival,  cell  adhesion, inflammation, 
differentiation and cell growth. The role of NF-κB in different steps 
of tumoriogenesis are:  
NF-κ  B ACTIVATION AND CELL PROLIFERATION 
  In normal cells,  NF-κB becomes activated only after the 
appropriate stimulation and then, upregulates the transcription of its 
target genes. In tumor cells,  different types of molecular alterations 
may result in impaired regulation of NF-κB activation. In such 
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cases, NF-κB loses its transient nature of activation and becomes 
constitutively activated. This leads to deregulated expression of NF-
κB controlled genes.2 7  
 Several genes that mediate cell  proliferation are regulated by 
NF-κB. These include growth factors such as TNF-α ,  IL-1β  and 
interleukin-6 (IL-6). Besides growth factors, certain cell cycle-
regulatory proteins (eg: the cyclin D1 required for transition of 
cells from G1 to S phase) are also regulated by NF-κB.28  
 In some cells,  PGE2 has been shown to induce proliferation of 
tumor cells.  The synthesis of cyclooxygenase-2 (COX-2), which 
controls PGE2 production, is also regulated by NF-κB activation. It  
has also been shown that growth factors such as EGF and platelet-
derived growth factor (PDGF) induce proliferation of tumor cells  
through activation of NF-κB.2 9 
ACTIVATION OF NF-κ  B PROMOTES SURVIVAL OF TUMOR 
CELLS 
 Gene products that negatively regulate apoptosis in tumor 
cells are controlled by NF-κB activation. These include IAP-1, IAP-
2, XIAP, cFLIP, TRAF1, TRAF2 and Bcl-xL. Tumor necrosis 
factor- alpha can cause programmed cell death (i .e,  apoptosis) and 
this is often paralleled by increased NF-κB activation. Inappropriate 





NF-κB may upregulate the mitochondrial antiapoptotic factor 
Bcl-2, perhaps in a positive feed back loop as Bcl-2 downregulates 
IκBα ,  thus increasing NF-κB activation. NF-κB has been linked to 
anti-apoptotic function in tumors such as T-cell lymphoma, 
melanoma, pancreatic cancer, bladder cancer and breast cancer and 
in tumor-related cell types such as B cells,  T cells,  granulocytes, 
macrophages, neuronal cells,  smooth muscle cells and osteoclasts.3 1  
NF-κ  B MEDIATES THE  INVASION OF TUMOR CELLS 
 NF-κB regulates many genes involved in the promotion of 
cancer by clonal expansion, growth, diversification, angiogenesis, 
adhesion, extravasation, degradation of extracellular matrix, etc. 
The development of cancer is generally categorized into three 
stages: tumor initiation, tumor promotion and tumor metastasis.  
Proteases influence tumor invasiveness (eg: the matrix 
metalloproteinases and the serine protease urokinase- type 
plasminogen activator [uPA]) which is regulated by NF-κB.32  
 Matrix metalloproteinases (MMPs) promote growth of cancer 
cells through the interaction of extracellular matrix (ECM) 
molecules and integrins, cleaving insulin-like growth factors and 
shedding transmembrane precursors of growth factors, including 
transforming growth factor-β  (TGF-β).  uPA is another critical 
protease involved in tumor invasion and metastasis.  Constitutively 
active phosphatidylinositol-3 kinase (P13K) controls cell  motility 
by regulating the expression of uPA through the activation of NF-
κB. Thus one potential way to block the invasion of tumors is to 
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target NF-κB so that the activation of genes involved in cancer 
progression is also blocked.33  
NF-κ  B ACTIVATION AND ANGIOGENESIS 
 Tumor cells just l ike normal cells,  need oxygen to survive and 
thus can be a limiting factor to progression of tumors. 
Vascularization of tumors requires the release of angiogenic growth 
factors (eg: VEGF, MCP-1) from tumor cells and/or inflammatory 
cells such as macrophages and neutrophils or in response to pro-
inflammatory cytokines. Angiogenesis is critical for tumor 
progression and this process is dependent on chemokines (eg: MCP-
1, IL-8) and growth factors (eg: vascular endothelial growth factor 
[VEGF]) produced by neutrophils and other inflammatory cells.  The 
production of these angiogenic factors has been shown to be 
regulated by NF-κB activation.3 4 ,35  
NF-κ  B AND METASTASIS 
 The metastasis of cancer requires the migration of cancerous 
cells both into and out of the vessel walls that transport them to 
other parts of the body. The abilty to cross vessel walls is mediated 
by specific molecules that are expressed in response to a number of 
signals from inflammatory cells,  tumor cells,  etc. Among those 
special molecules are ICAM-1, ELAM-1, and VCAM-1, all  of which 
have been shown to be expressed in response to NF-κB activation.3 6  
CONSTITUTIVE ACTIVATION OF NF-κ  B  IN CANCER 
 Potential mechanism through which NF-κB could play a role 
in tumorigenesis involves its constitutive activation. Activation of 
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NF-κB occurs as it  is  transported from the cytoplasm to the nucleus 
upon degradation of the inhibitory subunit.  In the nucleus it binds to 
specific κB sites on the DNA and mediates the expression of a 
number of genes involved in the cellular response to various 
stresses. Thus when NF-κB is found persistently in the nucleus, it  is 
referred to as constitutive activation.3 7  
 While many NF-κB stimuli have been identified, the stimulus 
responsible for constitutive activation of NF-κB in most cell types 
is not understood. Cells that express constitutively activated NF-κB 
are resistant to various chemotherapeutic agents.38  
CARCINOGENESIS AND NF-κB  
  Hideki Nakayama, Tetsuro Ikebe, Mahiro Beppu et al  
(2001) used   immunohistochemistry to examine the expression of 
NF-κB and the signaling molecules leading to NF-κB activation in 
36 untreated biopsy specimens from patients with squamous cell 
carcinoma (SCC) and in 15 specimens from patients with epithelial 
dysplasia of the oral cavity.The results suggest that high expression 
levels of p65 and IKKα  contribute to malignant behaviour and 
antiapoptotic activity in SCC of the oral squamous epithelium.4 4  
S. Chen, A. Fribly, and C. Y. Wang et al  (2002)  used 
enzyme linked immunosorbent assay and western blot analysis to 
explore the gene therapy approaches relevant to the inhibition of 
NF-κB signaling, to determine whether Adv-SR-IκBα   inhibited  
NF-κB activation in Oral Squamous Cell Carcinoma (OSCC) cells.  
The results of the in vitro  application of a gene therapy stratergy for 
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oral cancer treatment confirmed that OSCC cells are accessible to 
adenovirus-mediated gene transfer and the combination of gene 
therapy with IκBα  and TNF was efficient in the induction of 
apoptosis and OSCC cells.  Also inhibition of NF-κB by IκBα  gene 
transfer sensitizes OSCC cells to TNF killing.39  
Asha Nair, Manickam Venkatraman, Tessy T Maliekal et al  
(2003) have used several techniques such as immunohistochemistry, 
Western blotting, Semiquantitative Reverse Transcriptase –
Polymerase Chain  Reaction and Electrophoretic mobility shift 
assays, and provided evidences for the constitutive activation of   
NF-κB during cervical cancer progression using 106 paraffin-
embedded cervical tissue specimens of different histological grades. 
In normal cervical tissue and low grade squamous intraepithelial  
lesions, p50, RelA and IκB-α  were mainly localized in the cytosol,  
whereas in high-grade lesions and squamous cell  carcinomas, p50-
RelA heterodimers translocated into the nucleus with a concurrent 
decrease in IκB-α  protein.4 1  
Lan Li, Bharat B. Aggarwal, Shishir Shishodia et al  (2004) 
studied the ability of curcumin (diferuloylmethane), an agent that is  
pharmacologically safe in humans, to modulate NF-κB activity.  
Nuclear factor kappa B (NF-κB) has been determined to play a role 
in cell survival or proliferation in pancreatic carcinoma. 5-human 
pancreatic carcinoma cell lines were examined using electrophoretic 
mobility gel-shift assay and immunoblot analysis. 
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 Curcumin down-regulated NF-κB and growth control 
molecules induced by NF-κB in human pancreatic cells.  These 
effects were accompanied by marked growth inhibition and 
apoptosis. Through these findings, the authors provided a biologic 
rationale for the treatment of patients with pancreatic carcinoma 
using this nontoxic phytochemical.4 8  
Guido M. Sclabas, Tadashi Uwagawa, Christian Schmidt et 
al  (2005) studied the effects of aspirin on pancreatic carcinoma 
prevention and to reveal a possible mechanism of aspirin-mediated 
cancer chemoprevention. An orthotopic mouse model with human 
pancreatic carcinoma cell lines PANC-1, PANC-1/Puro, and PANC-
1/IκBαM was used to study the inhibitory effects of aspirin on 
pancreatic tumor formation.  It  was concluded that aspirin repressed 
tumor formation by PANC-1cells in vivo  in a prophylactic setting, 
suggesting a possible mechanism for aspirin’s preventive effect in 
pancreatic carcinoma through inhibition of NF-κB activation and a 
mechanistic link between inflammation and tumorigenesis.4 7  
An Immunohistochemical study by Alok Mishra, Alok 
Bharti,  Bhuder Das C et al  (2006) was done to analyze the 
activation of NF – κB and its alterations, in the expression of 
different NF – κB proteins during oral carcinogenesis in vivo  using 
tissue biopsies from precancerous and cancerous oral lesions. The 
role of high risk human papilloma virus (HPV – 16) which activates 
the p50 / p65 NF – κB complex formation, which promotes 
differentiation of oral neoplastic cells leading to better prognosis of 
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the oral cancer was also analysed. Here the total  biopsy specimens 
were 110,out of which 10 cases were normal (n = 10), 34 cases was 
oral precancer (n = 34) and 66 cases was cancer (n= 66).Expression 
of p50 protein was 1000 in all  the normal tissues and 40% of 
precancerous lesion & 70% of oral cancers showed moderate to high 
expression of NF – κB.1  
Ximing Tang, Diane Liu, Shishir Shishodia et al  (2006)  
showed Immunohistochemical expression of  NF-κB p65 in 394 lung 
cancers (370  non-small cell  lung carcinomas [NSCLC]; and 24 
small cell lung carcinomas[SCLC]) and 269 lung normal epithelium 
and preneoplastic lesions, including hyperplasias, squamous 
metaplasias, dysplasias, and atypical adenomatous hyperplasias.  
High levels of nuclear Immunohistochemical expression of   NF-κB 
p65 were detected in the lung cancers, with significantly higher 
levels in SCLCs compared with NSCLCs (P < 0.0001).  
 The findings indicate that NF-κB activation plays an 
important role in lung cancer pathogenesis and NF-κB p65 nuclear 
expression is an early and frequent phenomenon in the pathogenesis  
of lung cancer.42  
Ming Yu, Jason Yeh and Carter Van Waes et al  (2006) 
showed that CK2 contributes to the activation of IKK and NF-κB in 
response to serum factors, which suggests that CK2 and IKK2 are 
key candidates for targeting the NF-κB pathway in head and neck 
squamous cell carcinoma (HNSCC). NF-κB activation has been 
broadly shown and associated with progression in intraepithelial 
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premalignant and malignant squamous neoplasms of the head and 
neck as well as uterine cervix.43   
 Christine H. Chung, Joel S. Parker, Kim Ely, Jesse Carter 
et al  (2006) studied the  high- risk signature for disease recurrence 
using formalin-fixed  tissues of  HNSCC tumors and compared the 
results with an independent data set obtained from fresh frozen 
tumors. Gene expression was determined in 40 samples, including 
34 formalin-fixed tissues and 6 matched frozen tissues, from 29 
HNSCC patients.  A 75-gene list predictive of disease recurrence 
was determined by training on the formalin- fixed tumor data set 
and tested on data from the independent frozen tumor set from 60 
HNSCC patients.  They concluded that global gene expression 
analysis is feasible using formalin fixed tissue. The 75-gene list  can 
be used a prognostic biomarker of recurrence and our data suggest 
that the molecular determinants of EMT and NF-κB activation can 
be targeted as the novel therapy in the identified high-risk 
patients.4 6  
 Tin Lap Lee, Xin Ping Yang, Bin Yan, Jay Friedman et al  
(2007) studied gene signatures that was differentially expressed in 
head and neck squamous cell  carcinomas (HNSCC) that are related 
to alterations in transcription factor-κB (NF-κB) and TP53 
previously associated with decreased cell death, response to therapy 
and worse prognosis. Unique gene signatures expressed by HNSCC 
lines were identified by cDNA microarray, principal components, 
and cluster analyses and validated by quantitative reverse 
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transcription-PCR (RT-PCR) and in situ  hybridization. 
Bioinformatic analysis of the promoters and ontogeny of these 
cluster genes was done.  NF-κB promotes expression of a novel NF-
κB – related gene signature and cell survival in HNSCC that weakly 
express TP53, a subset previously associated with inactivated wild-
type TP53, greater resistance to chemoradiotherapy, and worse 
prognosis.4 5    
Zhong Chen, Bin Yan, Carter Van Waes et al  (2008) used 
immunohistochemistry (IHC), Reverse-phase protein microarray 
(RPMA), Western blot analysis and Enzyme linked Immunosorbant 
Assay (ELISA) to determine which pathways are activated and how 
they correlate with prognosis, select therapy targeting these 
pathways and to use changes in phosphorylation, expression of 
protein and functional changes such as TUNEL or caspase cleavage 
together as early biomarkers of response to the treatment.  
 Serum cytokines regulated by NF-κB represent biomarkers of 
response, recurrence and survival in HNSCC.40  
NF-κB AND LEUKOPLAKIA  
 Squamous cell  carcinoma is the most common malignancy of 
the oral cavity which is often preceded by premalignant lesions, the 
most common of  which  is leukoplakia.6 0  Epithelial malignancies of 
the oral cavity often begin as preneoplastic lesions in the form of 
inflammatory lesions such as leukoplakia. Leukoplakia is associated 
with tobacco and alcohol use and chronic inflammation with a 
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higher risk of malignant transformation to oral squamous cell  
carcinoma.63   
 Nuclear factor kappa B has been implicated in the 
development of head and neck squamous cell carcinoma from  
premalignancy, progression to invasion, metastasis and treatment  
resistance.5 1  Transcription factor NF-κ  B is an early response gene 
that is found to be elevated in subjects with tobacco use, chronic 
inflammatory conditions of oropharynx and head and neck cancer. 
Inflammatory gene expressions are induced by the downstream of 
cytokine and growth factor receptors, such as signal transducers and 
activators of transcription. The expression of NF-κ  B has been 
found to be gradually increasing from premalignant lesions to 
invasive cancer.6 2  
NF-κB AS A POTENTIAL MOLECULAR TARGET FOR 
CANCER THERAPY 
 NF-κB is constitutively activated in a large number of 
epithelial and hematologic malignancies, strongly suggest that NF-
κB inhibitors would be useful in cancer therapy. Inhibition of NF-
κB has been found to be an important mechanism of action of 
steroids, nonsteroidal anti-inflammatory drugs (NSAID) and natural 
and synthetic compounds that show therapeutic and preventive 
activity with acceptable safety profiles.4 9  
NSAIDS AND CANCER PREVENTION   
 NSAIDs such as aspirin, sulindac, ibuprofen, celecoxib, have 
been shown to inhibit NF-κB activation and arachidonic acid 
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inflammatory pathways upstream and downstream of NF-κB. 
Strategy for blocking NF-κB include an upstream strategy and a  
NF-κB targeting strategy.50 Blocking the activation of NF-κB 
signaling pathway using:  
a)  proteasome inhibitors (such as PS-341, MG 132);  
b) IKK inhibitors (such as NSAIDs, sulfa salazine, arsenic 
trioxide, curcumin, thlidomide);   
c)  cell-permeable peptides (such as SN-50); 
d) antioxidants (such as disulfiram, glutathione); or 
e)  the recombinant adenovirus-mediated overexpression of the 
IκBα  gene.  
On the other hand, the NF-κB targeting strategy includes:  
(a) blocking the DNA binding of  NF-κB using decoy 
oligodeoxynucleotides (ODNs) 
(b) blocking the transactivation of NF-κB using glucocorticoids 
(c) interfering with mRNA using NF-κB antisense 
oligonucleotide (ASO)51 ,5 2  
CORTICOSTEROIDS AND CYTOTOXIC AGENTS USED FOR 
THERAPY 
 The cytotoxic effects of corticosteroids in combination with 
other DNA-damaging agents led to the use of steroid-based 
regimens as a current mainstay of treatment of certain leukemias, 
lymphomas and myelomas. Subsequently, corticosteroids were 
shown to mediate many of their anti-inflammatory and tumor 
cytotoxic effects through inhibition of NF-κB, and these lymphoid 
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malignancies and supporting host responses were found to be 
exquisitely dependent on NF-κB regulated survival or inflammatory 
mechanisms.5 3 , 5 4  
PROTEASOME INHIBITORS 
 A new class of therapeutic agents under development are 
proteasome inhibitors, which regulate degradation of IκB and 
inhibit NF-κB, as well as turnover of other cellular proteins.55 ,56  
IKK INHIBITORS 
 IKKβ  antagonists that more specifically inhibit IκB and the 
NF-κB classic pathway initially implicated in cancers have been the 



















 Forty cases of  OSCC (Group I),  twenty cases of  Oral 
Leukoplakia (Group II) and Twenty cases of  normal mucosa (Group 
III) were analyzed for immunoreactivity of  NF-κ  B protein. All the 
samples in group I,  II and III  were taken from the buccal mucosa. 
 The patient’s age ranged from  35 to 92 years (mean 57.5  ± 
13.3) in group I from 26 to 59 years (mean 42.2  ± 10.1) in group II 
and  from  20 to 42 years (mean 27.9 ± 4.8) in group III (Table 1, 
Graph 1 ) 
 Of the forty patients in group I,  55% (n=22) were men and 
45% (n=18) were women. In group II all  the cases were men, 
whereas in group III,  70% (n= 14) were men and 30% (n=6) were 
women (Table 2, Graph 2) 
 Depending upon habits,  patients were segregated into Areca 
Chewers, Tobacco Chewers, Areca & Tobacco Chewers and Smokers 
& Chewers. In group I,  13% (n=5) of patients were Areca Chewers,  
43%  (n=17 ) of patients were Tobacco Chewers, and 28%  (n=11) 
were Areca & Tobacco Chewers,  3% (n=1) were both Smokers & 
Chewers and   15%  (n=6)  had  no habits.  Entire group III had no 
smoking or chewing habits (Table 3, Graph 3) 
 According to the histopathological grading in OSCC, 23% 
(n=18) of patients had well differentiated OSCC, 24% (n=19) of 
patients had moderately differentiated OSCC and 11% (n=9) of 
patients had poorly differentiated. 
 36 
 
Distribution of NF-κ  B Staining Among 3 Groups: 
 NF-κ  B revealed positivity in group I (Figure 7 & 8), group II 
(Figure 11& 12) and group III (Figure 15 & 16). In Group II 
positive staining was observed in 100 % of the cases, whereas in 
Group I and Group III,  positive staining was observed in 97% and 
80% respectively. 
Tissue localization of stain (Table 4, Graph 4)  
 NF – κB staining was seen both in the epithelium as well as in 
the connective tissue. In connective tissue the staining was seen in 
lymphocytes, muscle fibres and endothelial cells.      
 In group I,  65% (n=26) of cases showed nuclear staining in 
the epithelium and connective tissue, whereas in 35% (n=14) of 
cases showed cytoplasmic staining, In groupII 80% (n=16) showed  
nuclear  staining while 20% (n=4) showed   cytoplasmic staining 
and  in group III 35% (n=7)  showed  nuclear  staining and 65% 
(n=13) cases  showed  cytoplasmic staining. In connective tissue, 
staining was predominantly seen in lymphocytes, muscle f ibres and 










INTENSITY OF STAIN 
Distribution of staining intensity in the basal layers among the 
groups (Table 5, Graph5)   
In the basal layer, mild intensity of staining was seen in 18% (n=7) 
of OSCC, 20% (n=4) of leukoplakia and 15% (n=3) of normal cases. 
Moderate staining was seen in 45% (n=18) of OSCC , 45% (n=9) of 
leukoplakia and 30% (n=6) of normal cases whereas 35% (n=14) of 
OSCC, 35% (n=7) of leukoplakia and 35% (n=7) of normal cases 
showed  intense staining.  
Distribution of staining intensity in the suprabasal layers among 
the groups (Table 6,  Graph 6) 
 In the suprabasal layer, mild intensity of staining was seen in 
18% (n=7) of OSCC, 5% (n=1) of leukoplakia and 5% (n=1) of 
normal cases. Moderate staining was seen in 58% (n=23) of OSCC, 
70% (n=14) of leukoplakia and 65% (n=13) of normal cases whereas 
23% (n=9) of OSCC, 25% (n=5) of leukoplakia and  10% (n=2) of 
normal cases showed  intense staining. The results were statistically 
significant (p=0.048) 
Comparison of staining intensity in the connective tissue among 
the groups (Table 7,  Graph 7) 
 In 40 cases of OSCC 23% (n=9) and in normal 50% (n=10) 
showed no stain. Mild intensity of staining was seen in 18% (n=7) 
of OSCC,10% (n=2) of  both leukoplakia and normal cases. 
Moderate intensity of staining was seen in 35% (n=14) of OSCC and 
70% (n=14) of leukoplakia and 25% (n=5) of normal cases.  And 
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intense staining was seen in 25% (n=10) of OSCC and 20% (n=4) of 
leukoplakia and 15% (n=3) of normal cases. The results were 
statistically significant (p=0.007) 
Comparison of staining intensity in the epithelium and 
connective tissue among the groups (Table 8, Graph 8) 
 In 40 cases of OSCC 11.1% (n=1) and in 20 cases of normal 
40% (n=4) showed no stain both in the epithelium and in the 
connective tissue. Mild staining in the epithelium and no stain in 
the connective tissue was seen in 11.1% (n=1) cases of OSCC. 
Moderate staining in the epithelium and no stain in the connective 
tissue was seen in 66.7% (n=6) of OSCC and 60% (n=6) of normal 
cases. Moderate staining in the epithelium and mild staining in the 
connective tissue was seen in 100% (n=7) of OSCC, 100% (n=2) of 
leukoplakia and 50% (n=1) of normal cases. Moderate staining in 
the epithelium and intense staining in the connective tissue was 
seen in 100% (n=10) of leukoplakia and 33.3% (n=1) of normal 
cases. Intense staining in the epithelium and no stain in the 
connective tissue was seen in 11.1% (n=1) of OSCC. Intense 
staining in the epithelium and mild staining in the connective tissue 
was seen in 50% (n=1) of normal cases. Intense staining in the 
epithelium and moderate staining in the connective tissue was seen 
in 42.9% (n=6) of both OSCC and leukoplakia, 60% (n=3) of 
normal.  Intense staining in both the epithelium and connective 
tissue was seen in 100% (n=10) of OSCC and 66.7% (n=2) of 
normal. Staining intensity in the epithelium and connective tissue of 
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OSCC and leukoplakia were statistically significant and they were 
0.001 and 0.043 respectively.   
Comparison of mean labeling index among the study groups  
 In OSCC, 26/40 cases showed nuclear staining and their mean 
labeling index was 25.96.  In leukoplakia,  16/20 cases showed 
nuclear staining which had the mean labeling index as follows 
20.84.  In normal, 7/20 cases showed nuclear staining and its mean 
labeling index is 30.93, but this difference was not statistically 
significant (p=0.262). 
Comparison of mean labeling index between OSCC and normal, 
Leukoplakia and normal & OSCC and leukoplakia 
 Comparison of mean labeling index between OSCC (54.34) 
and normal (44.97) was done. Comparison of mean labeling index 
between leukoplakia (51.17) and normal (44.97) was done. Similarly 
the mean labeling index of OSCC (54.34) was compared to 
leukoplakia (51.17), but these differences were not statistically 
significant.  
 The inter-observer agreement for the intensity of stain for all  










TABLE 1: AGE OF THE SUBJECTS IN THE STUDY GROUPS 
Age 
Group I Group II Group III 
p value 
n % n % n % 
≤30 0 0 2 10 17 85 
0.000* 
31-50 15 38 13 65 3 15 
51-70 18 45 5 25 0 0 
≥71 7 18 0 0 0 0 
 
*p value ≤0.05 was considered to be statistically significant 
GRAPH 1: AGE OF THE SUBJECTS IN THE STUDY GROUPS 
 
Group I – OSCC 
Group II   – Leukoplakia 
Group III – Normal  
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n % n % 
Group I 22 55 18 45 
0.002* 
Group II 20 100 0 0 
Group III 14 70 6 30 
 
*p value ≤  0.05 was considered to be statistically significant 
GRAPH 2: DISTRIBUTION OF GENDER IN THE STUDY 
GROUPS  
 
Group I – OSCC 
Group II   – Leukoplakia 
Group III – Normal  
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TABLE 3: DISTRIBUTION OF HABITS IN THE STUDY 
GROUPS 
Habits 
Group I Group II 
p value 
n % n % 
Areca Chewers 5 13 1 5 
0.000* 
Tobacco Chewers 17 43 10 50 
Tobacco + Areca 11 28 4 20 
Smoking + Chewing 1 3 5 25 
No habits 6 15 0 0 
 
*p value ≤  0.05 was considered to be statistically significant 
GRAPH 3: DISTRIBUTION OF HABITS IN THE STUDY GROUPS 
 
Group I – OSCC 
Group II - Leukoplakia  
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NUCLEAR 65 80 35 
0.011*
CYTOPLASMIC 35 20 65 
 
*p value ≤  0.05 was considered to be statistically significant 
GRAPH 4: LOCALIZATION OF NF-κ  B STAINING AMONG 
THE GROUPS 
 
Group I – OSCC 
Group II – Leukoplakia 
Group III – Normal  
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TABLE 5: DISTRIBUTION OF STAINING INTENSITY IN THE 
BASAL LAYER AMONG THE GROUPS  
Intensity 
Group I Group II Group III 
p value 
n  % n  % n % 
No Stain 1 3 0 0 4 20 
0.165 
Mild 7 18 4 20 3 15 
Moderate 18 45 9 45 6 30 
Intense 14 35 7 35 7 35 
 
GRAPH 5: DISTRIBUTION OF STAINING INTENSITY IN THE 
BASAL LAYER AMONG THE GROUPS 
 Group I – OSCC 
Group II   – Leukoplakia 
Group III – Normal  
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TABLE 6: DISTRIBUTION OF STAINING IN THE 
SUPRABASAL LAYER AMONG THE GROUPS 
Intensity Group I Group II Group III p value 
n  % n  % n % 
No Stain 1 3 0 0 4 20  
 
0.048* 
Mild 7 18 1 5 1 5 
Moderate 23 58 14 70 13 65 
Intense 9 23 5 25 2 10 
*p value ≤  0.05 was considered to be statistically significant 
GRAPH 6: DISTRIBUTION OF STAINING IN THE 
SUPRABASAL LAYER AMONG THE GROUPS 
 Group I – OSCC 
Group II   – Leukoplakia 
Group III – Normal  
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TABLE 7: DISTRIBUTION OF STAINING INTENSITY IN THE 
CONNECTIVE TISSUE AMONG THE GROUPS 
Intensity Group I Group II Group III p value 
n  % n  % n % 
No Stain 9 23 0 0 10 50  
0.007* Mild 7 18 2 10 2 10 
Moderate 14 35 14 70 5 25 
Intense 10 25 4 20 3 15 
 
*p value ≤  0.05 was considered to be statistically significant 
GRAPH 7: DISTRIBUTION OF STAINING INTENSITY IN THE 
CONNECTIVE TISSUE AMONG THE GROUPS 
 
Group I  – OSCC 
Group II   – Leukoplakia 
Group III – Normal  
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TABLE 8: COMPARISON OF STAINING INTENSITY IN THE 




















 No stain Mild Moderate Intense 
n % n % n % n % 
No stain 1 11.1 0 0 0 0 0 0  
 
0.001* Mild 1 11.1 0 0 0 0 0 0 
Moderate 6 66.7 7 100 8 57.1 0 0 
Intense 1 11.1 0 0 6 42.9 10 100 
GROUP 
II 
Moderate -  -  2 100 8 57.1 10 100  
0.043* 
Intense -  -  0 0 6 42.9 0 0 
GROUP 
III 
No stain 4 40 0 0 0 0 0 0  
0.102 
Moderate 6 60 1 50 2 40 1 33.3 
Intense 0 0 1 50 3 60 2 66.7 
*p value ≤  0.05 was considered to be statist ically signif icant 
GRAPH 8: COMPARISON OF STAINING INTENSITY IN THE 
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 Nuclear factor κ  B (NF-κ  B) is a transcription factor that 
induces the expression of various genes, that influence 
inflammatory reactions, embryonic morphogenesis and 
antiapoptosis.  Intracellular signaling mechanism of NF-κ  B 
activation is effected by stimulators such as tumor necrosis factor α  
(TNF-α) and many other signals.44  An inhibitor of  NF-κ  B known 
as Iκ  B, which holds NF-κ  B in the cytoplasm gets phosphorylated 
and ubiquitinated by ubiquitin ligase and degraded by 26S 
proteosome and active NF-κ  B translocates from the cytoplasm into 
the nucleus and binds with the specific sequence in the promoter of 
target genes.37 These genes include pro-inflammatory cytokines, 
chemokines and cell survival genes. Activation of NF-κ  B plays a 
key role by which cells are resistant to TNF- mediated apoptosis, 
thus being associated with development and progression and 
metastasis of several malignancies including squamous cell 
carcinoma.39    
 Oral dysplasia is often a common precursor of oral cancer. 
Progression to cancer varies widely ranging from 5% to 20%. The 
assessment and severity of dysplasia is based on architectural 
disturbances accompanied by cytological atypia which are objective 
in nature. Since NF – κB is a transcription factor that is known to 
involve in growth, invasion and anti-apoptotic activity of cancer 
cells.  In this study we wanted to study expression in OSCC and 
leukoplakia and compare its activity with that of normal oral 
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mucosa to ascertain if it  could be used as a surrogate marker for 
malignant transformation.8  
PATIENT CHARACTERISTICS 
 In our study the mean age in OSCC cases was 57.5 ± 13.3 
years.   Mishra et al,  studied 66 cases of OSCC and reported the 
mean age in their study group as 52.9 ± 10.8 years. In the study 
done by Nakayama  et al,  the mean age was 70.2 years in 36 cases 
and Yu- Chao chang et al  reported age range from 50-59 years with 
a mean age of 55 years in 442 cases of OSCC. In a study by 
Ranganathan et al ,  the age ranged from 56-85 years with a mean 
age of 71.2 years in 10 cases.   
 In our study, the age presentation for leukoplakia ranged from 
26 to 59 years with a mean of 42.2 ± 10.1 years which is consistent 
with the study by Thavaraj et al with  a mean age of 36.67years in 
500 patients.   Yu- Chao chang et al  reported an age range from 20-
29 years and with a mean age of 25 years in 344 cases of oral  
leukoplakia. In the study by Lumerman et al  the age range was 25 
to 92 years with a mean age of 59.3 years.  
  In our study subjects who had OSCC were predominantly males 
and they constituted to about 70%. The male to female ratio was 
2.2:1 and this finding was consistent with that of   Napier et al  
where  the male: female ratio was 1.9:1 and  the male: female ratio 
was 3.9:1 with that of  Mishra et al .   
In our study all  the patients who had leukoplakia were males which 
is similar to a male: female ratio of  0.7 : 0.4 reported by 
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Saraswathi et al   in their study of 2017 patients at our centre 
earlier.  In a study by Thavaraj et al the male: female ratio was  
9.8:1 They also stated that number of males was around five times 
more than the females.    
  In this study, those patients who presented with OSCC, had 
the habit of chewing tobacco 17% and 5% of the patient had the 
habit of only Areca and about 11% of patients used both areca and 
tobacco .  This finding is consistent with that of Thavaraj et al  who 
reported that the majority of patients with OSCC in their study 
about 9.8% had the habit of chewing tobacco whereas 5.6% patients 
had the habit of only areca. 
 In this study, of 20 patients who presented with leukoplakia, 
10% had the habit of chewing tobacco and 4% had the habit of both 
areca nut and tobacco chewing.  These findings are consistent with 
that of Saraswathi et al  who reported that 10% of the patients had 
the habit of chewing areca nut and 8% had the habit of betel quid 
chewing.  
STAINING CHARACTERISTICS OF NF – κB   
 In our study, cytoplasmic expression of NF – κB   was seen in 
77.5% (n=31) of OSCC.  When we analysed the pattern of 
cytoplasmic staining, we observed that 17.5% (n=7) of the cases 
showed mild intensity of staining, while 35% (n=14) showed 
moderate and 25% (n=10) showed intense staining. Nuclear 
expression of NF – κB was seen in 65% (n=26) 0f cases. The 
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nuclear percentage positivity increased with increasing grade of 
OSCC.  
 Dysregulation of NF – κB expression and its activation is 
frequently observed in many human cancers.   Activated NF – κB 
shows nuclear expression and it  indicates an early event in 
carcinogenesis.   Once activated, it  controls the expression of 
several genes that regulate cell cycle (cyclin D1), differentiation 
(p2 1), cell  survival (Bcl – 2), growth factors (VEGF) cell adhesion 
(VCAM, ECAM) and angiogenesis (MMPs).  
 Our results were consistent with Nakayama et al  who also 
reported 78.2% cytoplasmic expression in 36 cases of OSCC.  There 
are other studies which states 64% of cytoplasmic expression as 
observed by Asha Nair et al.  The explanation for the absence of 
cytoplasmic expression of NF – κB in OSCC has not been indicated 
in this study. 
 In all these studies there was an association between tumor 
progression and extent of nuclear translocation of NF – κB.  In our 
study also the moderately differentiated OSCC exhibited increased 
nuclear expression which is consistent with tumor progression.  
Nakayama et al suggested that high expression level of NF – κB   
contributed to the malignant behavior and anti apoptotic activity of 
OSCC.  Mishra et al  reports that p50 homodimers transcriptionally 
regulate anti – apopotic Bcl -2 which is shown to be over expressed 
in oral cancer cells and inhibits terminal differentiation of oral 
keratinocyte.  The exact mechanism by which NF – κB is 
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constitutively activated in OSCC though not fully understood, it  has 
been suggested that autocrine expression of interleukins and EGFR 
may play an important role in the activation of NF – κB. 
 In inflammation associated cancer, non-genetic stimuli  
encourage the survival and proliferation of cells.   NF – κB has dual 
actions in tumor promotion; first by preventing the death of cells 
with malignant potential and second by stimulating the production 
of pro-inflammatory cytokines in inflammatory cells in tumor mass.  
These cytokines then signals the cell to promote their survival and 
proliferation.  Classical NF – κB pathway i.e,  the IKK – β  depedent 
NF – κB activation pathway might show the molecular link between 
inflammation and tumor promotion48 ,4 9.   So, in chronic 
inflammatory diseases, pro-inflammatory factors cause 
accumulation of DNA damage in dormant pre-malignant cells in 
tumor microenvironment to become malignant.44    
 In our study in leukoplakia, cytoplasmic expression of NF – 
κB was seen in 100% (n=20) of the cases.  When we analysed the 
pattern of staining, mild intensity of staining was observed in 10% 
(n=2) of case, 70% (n=14) showed moderate intensity, and 20% 
(n=4) showed intense cytoplasmic expression. Our study also 
showed nuclear expression of NF – κB in 80% (n=16) of cases.  
When we further analysed in order to understand the intensity of 
staining we observed that proliferating cells showed more staining 
than differentiated cells.   We observed that nuclear expression is 
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seen in those cases of leukoplakia which expressed histologically  
dysplastic alterations and an increase in inflammatory response.  
 Nayakama et al  observed 4% moderate staining and 11% of 
mild staining of NF – κB expression in the epithelium of 15 
dysplasia (leukoplakia) samples. They also reported that staining 
was seen in both basal and spinous epithelium cells and staining of 
NF – κB was seen in the basal epithelial cells of epithelial dysplasia 
(leukoplakia).  
 They suggest that NF – κB is an important mediator in 
chronic inflammatory process. Aberrant and persistent tissue 
inflammation is believed to play an important role in the occurence 
of tissue fibrosis and cancer. One of the etiological factors of 
leukoplakia is associated with area nut chewing habit.  They propose 
that areca nut extract was found to activate NF – κB in human oral 
keratinocytes and one of the pathogenic mechanisms of leukoplakia 
may be due to increased expression of NF – κB in response to areca 
nut.   NF – κB activates cytokines such as IL – 1 and TN F – α  which 
can result in amplification of inflammatory, response and 
persistence of chronic inflammation at local site.6 1   
  So, in leukoplakia we observed nuclear staining in 16% of 
the cases.  This nuclear expression of NF – κB by the epithelial  
cells is  correlated with the amount of cytotoxic cell infiltration 
suggesting that increased NF – κB activity may represent the basis 
of maintenance of the inflammatory response.  This can lead to the 
expression of genes that are mediated in carcinogens.  So, expression 
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of nuclear staining in leukoplakia can be used as an indicator for 
carcinogenesis. 
 The nuclear expression in our cases showed 
histopathologically a higher number of inflammatory cells which 
could account for its expressivity. We would like to corroborate our 
finding by studying more cases.   
 Compared to the normal cases the cytoplasmic intensity and 
nuclear immunoreactivity in OSCC and leukoplakia was increased 
and also we could find a statistically significant association 



















• The study group comprised of Group I  (OSCC n=40), Group II 
(leukoplakia n=20) and Group III (Normal n=20).  
• In OSCC, there was 98% positivity for NF – κB with 35% of 
cytoplasmic expression and 65% of nuclear expression.  
• In leukoplakia; there was 100% positivity for NF – κB 
expression; with 20% of cytoplasmic expression and 80% of 
nuclear staining. 
• In normal,  there was 80% of positivity for NF – κB 
expression within 65% of cytoplasmic expression and 35% of 
nuclear expression.   
• In OSCC and leukoplakia when the epithelial staining 
intensity was compared with the connective t issue staining 
intensity there was a statistically significant correlation 
(p=0.001) and (p=0.043) respectively.    
• Nuclear expression of NF – κB exhibited difference (p=0.011) 
between the groups. 
  In conclusion, our results show that there is increased 
expression of NF – κ  B in OSCC and leukoplakia when compared to 
normal.   Although the mean labeling index did not show any 
significant difference between OSCC and leukoplakia, further 
studies on a larger sample will help in ascertaining the exact role of 
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1. RHD  -  Rel Homology Domain 
2. IκB   -  Inhibitor of NF-κB 
3. IKK  -  IκB Kinase 
4. NEMO -  NF-κB Essential Modulator 
5. NIK  -  NF-κB inducing Kinase 
6. VCAM -  Vascular Cell Adhesion Molecule 
7. ICAM - Intercellular Cell Adhesion   
Molecule 
8. TRAF -  TNF – Receptor Associated Factor 
9. IAP  -  Inhibitor of Apoptosis Protein 
10. JNK  - Jun N-terminal Kinase 
11. TNF - Tumor Necrosis Factor 
12. IL  - Interleukins 
13. COX -  Cyclo oxygenase 
14. INOS -  Inducible Nitric Oxide Synthase 
15. MMP -  Matrix Metallo Proteinase 
16. uPA -  Serine protease urokinase – type          
                   plasminogen activator  
